Vertigo, characterized by a sensation of spinning or feeling off-balance, is a common clinical presentation in healthcare settings. It often poses diagnostic challenges due to its complex etiology. This article aims to provide a comprehensive clinical approach towards understanding and managing vertigo.
Vertigo can be categorized into peripheral and central, based on the anatomical origin. Peripheral vertigo, the most common type, originates from the inner ear or vestibular nerve, while central vertigo arises from the brainstem or cerebellum. Conditions such as benign paroxysmal positional vertigo (BPPV), Meniere's disease, and vestibular neuritis typically cause peripheral vertigo. In contrast, migraines, multiple sclerosis, and cerebrovascular diseases often result in central vertigo.
A detailed history and physical examination are crucial in differentiating between peripheral and central vertigo. The onset, duration, associated symptoms, and triggers can provide valuable clues. The Dix-Hallpike maneuver and the head impulse test are useful bedside tests. Neuroimaging may be warranted in cases of suspected central vertigo.
Treatment of vertigo is primarily directed towards the underlying cause. BPPV can often be managed with canalith repositioning maneuvers, while Meniere's disease may require dietary modifications and diuretics. Vestibular rehabilitation therapy can be beneficial for patients with persistent symptoms. Central vertigo necessitates a more detailed evaluation and management, often involving neurologists.
Vertigo is a multifaceted symptom that requires a thorough and systematic approach for accurate diagnosis and effective management. Understanding its etiology, performing a meticulous clinical assessment, and implementing appropriate management strategies are key to improving patient outcomes. Continued research and advancements in technology promise to further refine our clinical approach towards vertigo.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation